PIK3CD and breast cancer: The sensitivity of a group of breast cancer cell lines possessing mutations that activate the PI3K pathway to Akt inhibitors has been correlated with the expression of SGK1 in cell lines including ZR‐75‐1, CAMA‐1 and T47D (utilised in this study).